

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6959885

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MILLENNIUM PHARMACEUTICALS, INC.	05/03/2021
RECEIVING PARTY DATA		
Name:	TAKEDA PHARMACEUTICAL COMPANY LIMITED	
Street Address:	1-1, DOSHOMACHI 4-CHOME, CHUO-KU, OSAKA-SHI	
City:	OSAKA	
State/Country:	JAPAN	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15173393
CORRESPONDENCE DATA		
Fax Number:	(202)416-7212	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2028356212	
Email:	nhia.lee@bakermckenzie.com	
Correspondent Name:	BAKER & MCKENZIE LLP	
Address Line 1:	815 CONNECTICUT AVENUE, NW	
Address Line 2:	ATTN: PATENT DEPARTMENT	
Address Line 4:	WASHINGTON, D.C. 20006	
ATTORNEY DOCKET NUMBER:	50582642-0000	
NAME OF SUBMITTER:	NHIA LEE	
SIGNATURE:	/Nhia Lee/	
DATE SIGNED:	10/08/2021	
Total Attachments: 4		
source=EXECUTED - O4C_Millennium_MassGen_Confirmatory_Assignment#page1.tif		
source=EXECUTED - O4C_Millennium_MassGen_Confirmatory_Assignment#page2.tif		
source=EXECUTED - O4C_Millennium_MassGen_Confirmatory_Assignment#page3.tif		
source=EXECUTED - O4C_Millennium_MassGen_Confirmatory_Assignment#page4.tif		

CONFIRMATORY PATENT ASSIGNMENT

WHEREAS, on the 3rd day of May 2021, Millennium Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, and having a place of business at 40 Landsdowne Street, Cambridge, MA 02139 (the "Assignor"), was the owner of the patent(s) and application(s) identified in attached Schedule A ("the Patent(s)"); and

WHEREAS, on the 3rd day of May 2021, Takeda Pharmaceutical Company Limited, a public stock corporation organized under the laws of Japan and having a place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan (the "Assignee"), was desirous of acquiring the Patent(s), and related invention(s) thereof.

NOW, THEREFORE Assignor confirms that effective on the 3rd day of May 2021, for good and valuable consideration, the receipt of which was acknowledged therein and is hereby confirmed, Assignor sold, assigned and transferred unto said Assignee, and Assignee's successors and assigns, all right, title and interest in and to the Patent(s), and the invention(s) disclosed and claimed therein, and any Letters Patent which may thereafter be granted on the same in the United States and all countries throughout the world including any reissues, divisions, renewals, continuations in whole or in part, substitutions, conversions, reexaminations, prolongations, provisionals or extensions thereof, as well as rights to any and all existing causes of action and the right to past damages associated therewith, and all rights under the Paris Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patent(s) may be granted as fully and entirely as the same would have been held and enjoyed by Assignor had the sale and assignment not been made.

Assignor hereby further confirms that Assignee was granted the right to update the bibliographic information found in the attached Schedule A from time to time, including but not limited to adding the patent application numbers and patent numbers for those filings that fall under the scope of the above grant, such that this Agreement can be recorded with the respective global patent offices and ministries.

Assignee hereby grants a limited power of attorney for the purpose of recording this assignment in the United States and all other countries throughout the world to the practitioners listed on the power of attorney attached herewith and further grant the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or any other patent office worldwide for recordation of this document.

IN WITNESS WHEREOF, Assignor, by its duly authorized officer, has executed this Confirmatory Assignment in Wayland, Massachusetts, USA as of this 3rd day of May 2021.

ON BEHALF OF Millennium Pharmaceuticals, Inc.

By: *Lillian Hielt*

Printed Name: Lillian Hielt

Title: Authorized Signatory, IP Therapeutic Area Head, Oncology


STATE OF MASSACHUSETTS

COUNTY OF MIDDLESEX

§
266B
10

On this 3rd day of May 2021, before me, Noreen Buckley, Notary Public, personally appeared Lillian Hielt, personally known to me or identified by me to be the person whose name is subscribed to the within instrument and evidenced to me that they executed the same in their authorized capacity, and that by their signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.



Noreen Buckley

Noreen Buckley

NOTARY PUBLIC

My Commission Expires: 28 September 2023



NOREEN BUCKLEY

Notary Public


Commonwealth of Massachusetts

My Commission Expires

September 28, 2023

IN WITNESS WHEREOF, Assignee, by its duly authorized officer, has executed this Confirmatory Assignment in Sudbury, Massachusetts, USA as of this 3rd day of May 2021.

ON BEHALF OF Takeda Pharmaceutical Company Limited

By: 

Printed Name: Patrick Eaglerman

Title: Authorized Signatory, VP Intellectual Property


STATE OF MASSACHUSETTS


§
§
§

COUNTY OF MIDDLESEX

On this 3rd day of May 2021, before me, Noreen Buckley, Notary Public, personally appeared Patrick Eaglerman, personally known to me or identified by me to be the person whose name is subscribed to the within instrument and evidenced to me that they executed the same in their authorized capacity, and that by their signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.





Noreen Buckley

NOTARY PUBLIC

My Commission Expires: 28 September 2023

Schedule A

Patent Ref	Family	Status	Country	Application No.	Filed Date	Patent No.	Record Owner
MPI11-009P1RNCA2	MPI11-009	Pending	Canada	2853822	10/26/2012		Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNCN2	MPI11-009	Granted	China	201280065065.3	10/26/2012	ZL 201280065065.3	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNFR2	MPI11-009	Granted	France	12844605.1	10/26/2012	EP2775844	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNDE2	MPI11-009	Granted	Germany	12844605.1	10/26/2012	EP2775844	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNHK2	MPI11-009	Granted	Hong Kong	15102773.2	3/17/2015	HK1202224	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNIT2	MPI11-009	Granted	Italy	12844605.1	10/26/2012	EP2775844	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNJP2	MPI11-009	Granted	Japan	2014-539082	10/26/2012	6251176	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNES2	MPI11-009	Granted	Spain	12844605.1	10/26/2012	EP2775844	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNCH2	MPI11-009	Granted	Switzerland	12844605.1	10/26/2012	EP2775844	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNGB2	MPI11-009	Granted	United Kingdom	12844605.1	10/26/2012	EP2775844	Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital
MPI11-009P1RNCRCE	MPI11-009	Pending	USA	15/173393	6/3/2016		Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital

PATENT

RECORDED: 10/08/2021

REEL: 057758 FRAME: 0765